Furthermore, in both immune cohorts, the results of KM prognostic analysis showed that patients with high total score did have better survival when combined with high CD4 infiltration compared to low CD4 infiltration (Fig. 7B and D, P < 0.05), suggesting that CMTM4 combined with PD-L1 could affect CD4+ T cell immune infiltration to improve the immunotherapy effect and prognosis of tumor patients. This evidence concerns the gene CD274 and neoplasm.